Grace Therapeutics (GRCE) rose premarket as investors await an April 23 FDA verdict on GTx-104 for brain bleeds. Positive Phase 3 data showed a 19% reduction in hypotension and shorter hospital stays. The drug's Orphan Drug Designation offers seven years of market exclusivity if approved, making this a pivotal week for the biotech company.